



Anti-CCR8

High ADCC Anti-CCR8 for the Depletion of
T-regulatory Cells

CCR8 for Tumor-Infiltrating T_{reg} Depletion

Target Mechanism

Tumor-infiltrating Tregs highly express CCR8. iBio program targets depletion of highly immunosuppressive CCR8+ Tregs in tumor microenvironment via an ADCC mechanism.


Potential Indications

- Broadly applicable in solid tumors
- Prospective combination therapy

Differentiation / Opportunity

- Selective binding to CCR8 over its close homolog, CCR4

Recent Transactions & Milestones




*Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021.

**Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody.

*** Coherus / Surface Oncology: acquisition, announced in June 2023, adds two clinical assets, including a phase 2 anti-IL-27 and a phase 1/2 anti-CCR8 for oncology.

CCR8+ T_{reg} Cells Are Tumor Infiltrating and Highly Immunosuppressive


Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity




Afucosylated Anti-CCR8 Antibody Exhibits High Specificity, CCL1 Antagonism and CCR8-Specific Cell Killing

High Specificity CCR8 Cell Binding


Potent binding to CCR8 overexpressing cells




CCR8-CCL1 Antagonism



No binding to CCR4 overexpressing cells



PBMC-Induced CCR8 Cell Killing



iBio's CCR8-Specific High ADCC Antibody Induces Tumor Regression in a Transgenic Human CCR8 Mouse Model

